Skip to main content
AmigoFish

Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal

From Pharmaceutical Executive · · 3 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.

Back to Pharmaceutical Executive · Report a problem